Sarclisa is a novel anti-CD38 monoclonal antibody. Although antibodies are a naturally-occurring part of the immune system, Sarclisa and other antibodies used to treat diseases are made in a laboratory. A laboratorymade antibody is designed to
function like a naturally-occurring antibody, and to bind to a specific single protein on the surface of the targeted cells (in
this case, myeloma cells). In this sense, Sarclisa is a targeted antimyeloma therapy.